GLDN MAJOR CHART PLAY Gold Dynamics Corp. Geochemistry

New Post Public Reply Private Reply Replies (0) Message Board

Jan 28, 2013 at 9:20 AM

GLDN >> MAJOR CHART PLAY

Gold Dynamics Corp. Geochemistry Confirms Gold on Hoyle North Property
Press Release: Gold Dynamics Corp. – Tue, Dec 11, 2012 10:02 AM EST
Email
RecommendTweet
Print
RELATED QUOTES
Symbol Price Change
GLDN 0.01

TORONTO, ONTARIO--(Marketwire - Dec 11, 2012) - Gold Dynamics Corp. (GLDN) (GLDN)(GLDN) (www.golddynamics.com) -
Gold Dynamics Corp. is pleased to announce that 48 soil samples previously taken from their Hoyle North property were resubmitted for organic geochemistry analysis to Activation Laboratories (Actlabs) located in their Ancaster, Ontario facility. The testing utilized Soil Gas Hydrocarbon (SGH) Geochemistry and the samples were tested solely for the presence of gold. SGH is a deep penetrating geochemistry and has been proven to locate gold and other types of mineralization at several hundred metres below the surface irrespective of the type of overburden. The Hoyle North samples provided represent four North-South trending transects spaced at 100 metres apart, samples were spaced at 25 metres along each transect.
Actlabs reports the samples provided represent an excellent level of analytical performance and assign an SGH signature rating related to gold mineralization of 5.0 out of a possible 6.0 scale. The assigned 5.0 rating means that the SGH classes most important to describing a gold signature are all present and consistently describe the same location with well defined anomalies.
Mr. Gary Kirk, President and CEO of Gold Dynamics Corp said, "I continue to be impressed with the results of our surface exploration which serve to heighten my expectations that our efforts will be rewarded when we go subsurface. A clearer picture is being presented to me and the data base of known facts on the Hoyle North Project continues to expand and brighten from our efforts. I expect the property will continue to provide us higher hopes for exploration successes as our targets become more defined for that time we turn the drills."
Forward-Looking Statements
This current report contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, or the generation of positive cash flow as a result, updating of the corporate website or the availability of an independent geological report outlining the leases, their production, and their potential.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with mineral exploration and difficulties associated with obtaining financing on acceptable terms. We are not in control of gold prices and these could vary to make development uneconomic. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact:
Gold Dynamics Corp.
Corporate Information:
949-419-6588
info@golddynamics.com
Gold Dynamics Corp.
Investor Relations:
289-388-6122
gkirk@golddynamics.com
www.golddynamics.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Smirnoff Launches Marvel Event with $12.99 Offer

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Ameritas Hires Actuarial Veteran as VP in Strategic Move

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Amgen Q3 2026 Results: What Investors Should Know

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Royce Global Trust: Insights on RGT's Performance

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

transcosmos: Not Just Calls—Evolving Business Strategy

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Bloomberg Law Awards Series Celebrates Legal Excellence

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Oracle's Bold Vision: Targeting $225B Revenue by 2030

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

BD's New Liverty™ TIPS Stent: A Game Changer?

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Ascletis' ASC30 Achieves Significant HbA1c Reductions

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...